Brooks Gabriel 4
4 · Solid Biosciences Inc. · Filed Feb 2, 2026
Research Summary
AI-generated summary of this filing
Solid Biosciences (SLDB) CMO Brooks Gabriel Sells 28,335 Shares
What Happened
Dr. Brooks Gabriel, Chief Medical Officer of Solid Biosciences (SLDB), had performance stock units (PSUs) and restricted stock units (RSUs) convert to common stock following a performance milestone. A portion of the resulting shares — 28,335 shares — were sold in the open market on Feb 2, 2026 for total gross proceeds of $182,390 (weighted average price $6.44) to cover tax withholding. Several derivative transactions (exercises/conversions and grants) are reported on Jan 29 and Jan 31, 2026 reflecting the vesting/conversion activity.
Key Details
- Primary sale: 28,335 shares sold on 2026-02-02; weighted average price $6.44; proceeds $182,390. Sales executed across prices $6.295–$6.580. (F5)
- Conversions/exercises: PSUs/RSUs and option-related entries reported on 2026-01-29 and 2026-01-31 (multiple line items showing conversions/exercises and grants). PSUs/RSUs convert one-for-one to common stock. (F1, F3)
- Reason for sale: Sell-to-cover to satisfy tax withholding after PSU vesting; not a discretionary trade (automated sell-to-cover instruction adopted Aug 15, 2024). (F4)
- Vesting trigger: One performance milestone for PSUs (granted June 11, 2024) was certified met on Jan 29, 2026, causing vesting of 25% of target shares. (F6)
- Other notes: Filing references grants and vesting schedules for newly granted options and RSUs (vesting over four years). The filing also notes 4,152 shares acquired under the company ESPP on Nov 28, 2025. (F2, F7–F9)
- Filing timeliness: Report covers transactions on Jan 29–Jan 31, 2026 and was filed on Feb 2, 2026 — filed within Form 4 timing requirements (no late filing indicated).
Context
- These transactions are primarily derivative conversions (PSUs/RSUs) and a subsequent automatic sell-to-cover to pay taxes; that kind of sale is routine following vesting and does not by itself signal a discretionary decision to exit a position.
- For derivative activity: PSUs converted to RSUs/stock and certain option/award grants with multi-year vesting schedules were recorded; some of the converted shares were immediately sold to cover taxes (cashless/sell-to-cover mechanics).
- The filing does not provide an explicit aggregate total of shares owned by Dr. Gabriel after these transactions in the supplied data.
Insider Transaction Report
Form 4
Brooks Gabriel
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
[F1][F2]2026-01-29+58,847→ 96,818 total - Exercise/Conversion
Common Stock
[F3]2026-01-31+28,225→ 125,043 total - Sale
Common Stock
[F4][F5]2026-02-02$6.44/sh−28,335$182,390→ 96,708 total - Exercise/Conversion
Performance Stock Units
[F1][F6]2026-01-29−58,847→ 0 total→ Common Stock (58,847 underlying) - Award
Employee Stock Option (Right to Buy)
[F7]2026-01-29+207,450→ 207,450 totalExercise: $6.60Exp: 2036-01-29→ Common Stock (207,450 underlying) - Award
Restricted Stock Units
[F3][F8]2026-01-29+103,750→ 103,750 total→ Common Stock (103,750 underlying) - Exercise/Conversion
Restricted Stock Units
[F3][F9]2026-01-31−28,225→ 84,675 total→ Common Stock (28,225 underlying)
Footnotes (9)
- [F1]Each performance stock unit ("PSUs") converts to common stock on a one-for-one basis (the "PSUs").
- [F2]Includes 4,152 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on November 28, 2025.
- [F3]Each restricted stock unit ("RSUs") converts to common stock on a one-for-one basis.
- [F4]This sale was made to cover withholding taxes following the vesting of previously granted PSUs pursuant to a durable automatic sale instruction letter adopted by Dr. Brooks on August 15, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Dr. Brooks.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.295 to $6.580, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form.
- [F6]The PSUs were granted on June 11, 2024 and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"), subject to the grantee's continued service with the Company (the "Approval Conditions"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the first Performance Milestone was determined to be met on January 29, 2026 (the "2026 Grant Date") resulting in the vesting of the PSUs as to 25% of the underlying shares.
- [F7]This option was granted on the 2026 Grant Date and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the 2026 Grant Date and 2.0833% of the original number of shares monthly thereafter until the fourth such anniversary.
- [F8]The RSUs were granted on the 2026 Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the 2026 Grant Date until the fourth such anniversary.
- [F9]On January 31, 2025 (the "2025 Grant Date"), the reporting person was granted 112,900 RSUs, with 25% of the original number of shares vesting on each anniversary of the 2025 Grant Date until the fourth such anniversary.
Signature
/s/ Kimberly Cornwell as attorney-in-fact for Gabriel Brooks|2026-02-02